Siu L L, Moore M J
Department of Medicine, Princess Margaret Comprehensive Cancer Centre, University of Toronto, Ontario, Canada.
Semin Urol Oncol. 1997 Feb;15(1):20-7.
This article reviews the role of systemic chemotherapy in the treatment of hormone refractory prostate cancer, with emphasis on the evidence regarding the use of mitoxantrone plus prednisone, suramin, and various investigational regimens. Outcome assessment in this disease has not been uniform; recently evolved measures such as patient-based "palliative" endpoints and prostate-specific antigen responses will be discussed.
本文回顾了全身化疗在激素难治性前列腺癌治疗中的作用，重点阐述了有关米托蒽醌加泼尼松、苏拉明及各种试验性治疗方案应用的证据。对该疾病的疗效评估尚无统一标准；本文将讨论近期逐渐形成的一些评估指标，如基于患者的“姑息性”终点指标及前列腺特异性抗原反应。
